India, the world's largest supplier of generic medicines, must now expand into high-value pharmaceuticals and API manufacturing, economists say. Responding to a NITI Aayog report, experts called for stronger PLI support, greater investment in research and innovation, and reduced regulatory barriers to boost exports and strengthen India's position in advanced global pharma markets.